Less than three years after forming BlueRock Therapeutics with Versant Ventures, Bayer has now moved to fully acquire BlueRock which focuses on engineered cell therapies in the areas of neurology, cardiology and immunology. The deal lays the foundation for Bayer’s cell therapy franchise and reinforces the company’s interest in induced pluripotent stem cells, on the back of investments by Bayer’s venture arm in both Khloris Biosciences and Century Therapeutics in 2019.